Royal Pharmaceutical Society hosts debate on legal status of cannabis

Warning message

The subscription service is currently unavailable. Please try again later.

The Royal Pharmaceutical Society (RPS) will host a debate on whether the legal status of cannabis should be changed from a Schedule 1 to a Schedule 2 drug at its annual conference on Monday 14 September.  
Some argue a change in the listing would make it easier to research the drug’s potential to provide treatments for cancer, multiple sclerosis, Attention Deficit Hyperactivity Disorder (ADHD) and pain relief. 

A Schedule 1 listing under the Misuse of Drugs Regulations 2001 is given to drugs considered to have no medicinal use and potential for harm and abuse. 

Research into a Schedule 1 drug needs approval from the Home Office and includes purchase of a special licence which costs £4700 and can take up to a year to arrange.  In addition, bespoke security arrangements are required at additional cost when storing or obtaining the drug, as well as regular Police checks on...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.